MedTrace Logo

Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment

NCT01865448 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-06-20

Study results available
· View outcomes & findings →

Summary

Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional DHA omega-3 fatty acids supplements to increase the levels of pro-resolving and anti-inflammatory lipid mediators and decrease the biological markers of chronic inflammation in obese patients following a weight-loss programme.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 DHA

Patients take daily 2 tablets of Docosahexaenoic Acid

OTHER

Placebo

Patients in control group take daily 2 placebo capsule

Sponsors & Collaborators

  • Protein Supplies SL

    lead OTHER

Principal Investigators

  • Daniel De Luis, PhD · Unidad de Apoyo a la Investigacion. Hospital Rio Hortega

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-12-31
Completion
2015-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01865448 on ClinicalTrials.gov